FY2025 EPS Estimates for Exelixis Reduced by Leerink Partnrs

Exelixis, Inc. (NASDAQ:EXEL) – Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for shares of Exelixis in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now anticipates that the biotechnology company will post earnings per share of $2.10 for the year, down from their previous forecast of $2.15. The consensus estimate for Exelixis’ current full-year earnings is $1.74 per share.

Several other analysts have also commented on the stock. JMP Securities reiterated a “market outperform” rating and issued a $41.00 price target on shares of Exelixis in a research report on Thursday, January 23rd. TD Cowen increased their target price on Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a report on Monday, October 21st. The Goldman Sachs Group raised Exelixis to a “strong sell” rating in a report on Tuesday, October 15th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Exelixis in a research note on Monday, January 27th. Finally, BMO Capital Markets downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and boosted their target price for the company from $36.00 to $40.00 in a research note on Friday, December 20th. One analyst has rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, Exelixis has an average rating of “Moderate Buy” and an average target price of $36.06.

Exelixis Trading Down 2.1 %

Shares of NASDAQ EXEL opened at $32.81 on Monday. The company’s 50-day moving average price is $34.30 and its 200 day moving average price is $30.71. Exelixis has a 52 week low of $20.01 and a 52 week high of $37.59. The stock has a market cap of $9.37 billion, a price-to-earnings ratio of 21.03, a PEG ratio of 0.63 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 22.43% and a return on equity of 20.99%.

Insider Buying and Selling

In other news, EVP Patrick J. Haley sold 10,000 shares of the business’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $35.27, for a total value of $352,700.00. Following the completion of the sale, the executive vice president now owns 278,665 shares of the company’s stock, valued at approximately $9,828,514.55. The trade was a 3.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jeffrey Hessekiel sold 60,000 shares of Exelixis stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the transaction, the executive vice president now owns 486,059 shares of the company’s stock, valued at $17,823,783.53. This trade represents a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 111,588 shares of company stock valued at $3,981,864. Company insiders own 2.85% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Los Angeles Capital Management LLC raised its stake in Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after acquiring an additional 991,494 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Exelixis by 82.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock worth $52,884,000 after purchasing an additional 704,786 shares during the period. Globeflex Capital L P lifted its holdings in shares of Exelixis by 203.8% in the 4th quarter. Globeflex Capital L P now owns 975,151 shares of the biotechnology company’s stock worth $32,473,000 after purchasing an additional 654,200 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec bought a new stake in shares of Exelixis in the 3rd quarter worth approximately $14,979,000. Finally, Raymond James Financial Inc. acquired a new position in Exelixis during the 4th quarter valued at approximately $17,046,000. Institutional investors own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.